Please try another search
For the fiscal year ended 31 December 2015, SkyePharma PLC revenues increased 24% to L91.2M. Net income totaled L26.3M vs. loss of L11.7M. Revenues reflect Switzerland segment increase of 51% to L35.9M, Japan segment increase from L10M to L20.3M. Net Income reflects Interest decrease of 81% to L1.3M (expense), Exceptional costs decrease from L1.1M (expense) to L0K.
Period Ending: | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 55.1 | 38.6 | 39.4 | 34.4 |
Gross Profit | 30.9 | 19.7 | 19.7 | 21.2 |
Operating Income | 19 | 12.5 | 8.4 | -12.3 |
Net Income | 17.2 | 9.1 | 6 | -17.7 |
Period Ending: | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 103.2 | 89.3 | 92.3 | 90.9 |
Total Liabilities | 53.3 | 52.8 | 68.7 | 68.3 |
Total Equity | 49.9 | 36.5 | 23.6 | 22.6 |
Period Ending: | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 25.2 | 8.6 | 29.9 | 8.7 |
Cash From Investing Activities | -4.4 | -1.3 | -2.8 | -1.2 |
Cash From Financing Activities | -13 | -12.7 | -11.1 | 2.8 |
Net Change in Cash | 8.7 | -4.8 | 15.9 | 9.8 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review